BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer

Daniel J. Coleman, Lina Gao, Carly J. King, Jacob Schwartzman, Joshua Urrutia, Archana Sehrawat, Junior Tayou, Ariel Balter, Julja Burchard, Kami E. Chiotti, Daniel S. Derrick, Duanchen Sun, Zheng Xia, Laura Heiser, Joshi Alumkal

Research output: Contribution to journalArticle

Abstract

BET bromodomain inhibitors block prostate cancer cell growth at least in part through c-Myc and androgen receptor (AR) suppression. However, little is known about other transcriptional regulators whose suppression contributes to BET bromodomain inhibitor anti-tumor activity. Moreover, the anti-tumor activity of BET bromodomain inhibition in AR-independent castration-resistant prostate cancers (CRPC), whose frequency is increasing, is also unknown. Herein, we demonstrate that BET bromodomain inhibition blocks growth of a diverse set of CRPC cell models, including those that are AR-independent or in which c-Myc is not suppressed. To identify transcriptional regulators whose suppression accounts for these effects, we treated multiple CRPC cell lines with the BET bromodomain inhibitor JQ1 and then performed RNA-sequencing followed by Master Regulator computational analysis. This approach identified several previously unappreciated transcriptional regulators that are highly expressed in CRPC and whose suppression, via both transcriptional or post-translational mechanisms, contributes to the anti-tumor activity of BET bromodomain inhibitors.

Original languageEnglish (US)
JournalOncogene
DOIs
StatePublished - Jan 1 2019

Fingerprint

Androgen Receptors
Castration
Prostatic Neoplasms
RNA Sequence Analysis
Neoplasms
Growth
Cell Line

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. / Coleman, Daniel J.; Gao, Lina; King, Carly J.; Schwartzman, Jacob; Urrutia, Joshua; Sehrawat, Archana; Tayou, Junior; Balter, Ariel; Burchard, Julja; Chiotti, Kami E.; Derrick, Daniel S.; Sun, Duanchen; Xia, Zheng; Heiser, Laura; Alumkal, Joshi.

In: Oncogene, 01.01.2019.

Research output: Contribution to journalArticle

Coleman, DJ, Gao, L, King, CJ, Schwartzman, J, Urrutia, J, Sehrawat, A, Tayou, J, Balter, A, Burchard, J, Chiotti, KE, Derrick, DS, Sun, D, Xia, Z, Heiser, L & Alumkal, J 2019, 'BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer', Oncogene. https://doi.org/10.1038/s41388-019-0815-5
Coleman, Daniel J. ; Gao, Lina ; King, Carly J. ; Schwartzman, Jacob ; Urrutia, Joshua ; Sehrawat, Archana ; Tayou, Junior ; Balter, Ariel ; Burchard, Julja ; Chiotti, Kami E. ; Derrick, Daniel S. ; Sun, Duanchen ; Xia, Zheng ; Heiser, Laura ; Alumkal, Joshi. / BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. In: Oncogene. 2019.
@article{b9424b477c8f4c959790ec515f735a09,
title = "BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer",
abstract = "BET bromodomain inhibitors block prostate cancer cell growth at least in part through c-Myc and androgen receptor (AR) suppression. However, little is known about other transcriptional regulators whose suppression contributes to BET bromodomain inhibitor anti-tumor activity. Moreover, the anti-tumor activity of BET bromodomain inhibition in AR-independent castration-resistant prostate cancers (CRPC), whose frequency is increasing, is also unknown. Herein, we demonstrate that BET bromodomain inhibition blocks growth of a diverse set of CRPC cell models, including those that are AR-independent or in which c-Myc is not suppressed. To identify transcriptional regulators whose suppression accounts for these effects, we treated multiple CRPC cell lines with the BET bromodomain inhibitor JQ1 and then performed RNA-sequencing followed by Master Regulator computational analysis. This approach identified several previously unappreciated transcriptional regulators that are highly expressed in CRPC and whose suppression, via both transcriptional or post-translational mechanisms, contributes to the anti-tumor activity of BET bromodomain inhibitors.",
author = "Coleman, {Daniel J.} and Lina Gao and King, {Carly J.} and Jacob Schwartzman and Joshua Urrutia and Archana Sehrawat and Junior Tayou and Ariel Balter and Julja Burchard and Chiotti, {Kami E.} and Derrick, {Daniel S.} and Duanchen Sun and Zheng Xia and Laura Heiser and Joshi Alumkal",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41388-019-0815-5",
language = "English (US)",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer

AU - Coleman, Daniel J.

AU - Gao, Lina

AU - King, Carly J.

AU - Schwartzman, Jacob

AU - Urrutia, Joshua

AU - Sehrawat, Archana

AU - Tayou, Junior

AU - Balter, Ariel

AU - Burchard, Julja

AU - Chiotti, Kami E.

AU - Derrick, Daniel S.

AU - Sun, Duanchen

AU - Xia, Zheng

AU - Heiser, Laura

AU - Alumkal, Joshi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - BET bromodomain inhibitors block prostate cancer cell growth at least in part through c-Myc and androgen receptor (AR) suppression. However, little is known about other transcriptional regulators whose suppression contributes to BET bromodomain inhibitor anti-tumor activity. Moreover, the anti-tumor activity of BET bromodomain inhibition in AR-independent castration-resistant prostate cancers (CRPC), whose frequency is increasing, is also unknown. Herein, we demonstrate that BET bromodomain inhibition blocks growth of a diverse set of CRPC cell models, including those that are AR-independent or in which c-Myc is not suppressed. To identify transcriptional regulators whose suppression accounts for these effects, we treated multiple CRPC cell lines with the BET bromodomain inhibitor JQ1 and then performed RNA-sequencing followed by Master Regulator computational analysis. This approach identified several previously unappreciated transcriptional regulators that are highly expressed in CRPC and whose suppression, via both transcriptional or post-translational mechanisms, contributes to the anti-tumor activity of BET bromodomain inhibitors.

AB - BET bromodomain inhibitors block prostate cancer cell growth at least in part through c-Myc and androgen receptor (AR) suppression. However, little is known about other transcriptional regulators whose suppression contributes to BET bromodomain inhibitor anti-tumor activity. Moreover, the anti-tumor activity of BET bromodomain inhibition in AR-independent castration-resistant prostate cancers (CRPC), whose frequency is increasing, is also unknown. Herein, we demonstrate that BET bromodomain inhibition blocks growth of a diverse set of CRPC cell models, including those that are AR-independent or in which c-Myc is not suppressed. To identify transcriptional regulators whose suppression accounts for these effects, we treated multiple CRPC cell lines with the BET bromodomain inhibitor JQ1 and then performed RNA-sequencing followed by Master Regulator computational analysis. This approach identified several previously unappreciated transcriptional regulators that are highly expressed in CRPC and whose suppression, via both transcriptional or post-translational mechanisms, contributes to the anti-tumor activity of BET bromodomain inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85064657779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064657779&partnerID=8YFLogxK

U2 - 10.1038/s41388-019-0815-5

DO - 10.1038/s41388-019-0815-5

M3 - Article

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -